// Biotech and Pharma Therapeutics
Nationwide IV fluid shortage changing how hospitals manage patient hydration
November 19, 2024 / IV Fluid Shortage / Hospital Hydration Strategies / Hurricane Helene / Patient Care Innovations
A nationwide IV fluid shortage caused by Hurricane Helene is driving hospitals to adopt conservation measures, such as push medications and patient hydration through oral fluids, while balancing patient safety amid increased seasonal demand.
Health system CIOs’ strategic responsibilities continue to evolve
November 19, 2024 / Healthcare CIO Responsibilities / Digital Transformation / Healthcare / AI Adoption / Cybersecurity
Healthcare CIOs are assuming broader roles in strategy and digital transformation, prioritizing AI adoption, cybersecurity, and workforce expansion, with high turnover highlighting the need for competitive compensation, skill development, and flexible work models.
VBI recalls PreHevbrio and winds down operations
November 19, 2024 / PreHevbrio Recall / Hepatitis B Vaccine / Vaccine Distribution Halt / Healthcare Product Recall
VBI Vaccines has voluntarily recalled PreHevbrio (hepatitis B vaccine) amid its bankruptcy and operational shutdown. Healthcare providers have been instructed to halt distribution and administration of the product following the company’s restructuring decision.
The Role of Clinical Collaboration Platforms in Enhancing Sepsis Care Workflows
November 19, 2024 / Sepsis Care Workflow / Clinical Collaboration Platforms / Real-time Healthcare Communication / Sepsis Mortality Reduction
Clinical collaboration platforms enhance sepsis care by streamlining communication, enabling rapid response, and reducing delays. Real-time tools improve diagnosis, treatment initiation, and patient outcomes, addressing sepsis’s high mortality and significant healthcare costs.
Drugmakers and pharmacists battle over who gets to make obesity drugs
November 20, 2024 / Ozempic Compounding Dispute / Weight-loss Drug Shortages / Semaglutide Market Battle / Compounded Obesity Drugs / Trizepatide Safety Concerns
Demand for obesity and diabetes drugs like Ozempic has fueled a dispute between drugmakers and compounding pharmacies over legality and safety. The debate leaves patients facing limited access and potential risks from counterfeit alternatives.
// 4th Industrial Revolution
Addressing sexual health stigma in Singapore through telehealth
November 19, 2024 / Secual Health / Telehealth / Singapore / Discreet STD Testing Online
Quinn leverages telehealth to address sexual health stigma in Singapore, offering discreet consultations, testing, and treatments. Its secure platform fosters openness and accessibility while overcoming cultural barriers to improve patient trust and engagement.
First AI gut health service in Malaysia launched
November 19, 2024 / AI Gut Health Malaysia / Microbiome Testing / SpaceGut Health Service / Gut-related Health Solutions
SpaceGut launched Malaysia’s first AI-powered gut health service, offering at-home microbiome testing and personalized recommendations. Addressing Malaysia’s rising gut-related health issues, it uses AI to analyze health markers and plans future wellness expansions.
Telehealth Advocates Praise DEA’s 3rd Extension of Telemedicine Flexibilities, but Call for Further Action
November 19, 2024 / Telehealth Controlled Substances / DEA Telemedicine Extension / Telehealth Addiction Care / Virtual Prescribing Regulations
The DEA’s third extension of telehealth flexibilities for controlled substance prescriptions ensures continued access through 2025, but advocates urge permanent frameworks to modernize healthcare and secure vital care for underserved and addiction-recovery populations.
Too many IT systems with limited alignment impacts care quality
November 19, 2024 / Healthcare It Fragmentation / Clinical Burnout Solutions / Streamlining Healthcare Workflows / Showdow It in Healthcare
The symplr 2024 Compass Survey highlights how fragmented IT systems, administrative burdens, and leadership misalignment in healthcare lead to inefficiencies, clinician burnout, and reduced care quality. Streamlined workflows and technology consolidation are critical to future readiness.
Healthcare AI and Implementing AI Responsibly with enGen
November 19, 2024 / Responsible AI in Healthcare / Healthcare Innovation / enGen Healthcare
At HLTH 2024, enGen highlighted responsible AI implementation in healthcare, emphasizing predictive AI’s role in improving outcomes, controlling costs, and enhancing care delivery. Collaboration and data-driven solutions are central to achieving impactful and ethical AI use.
// Business & Markets
Medtronic lifts annual profit view on steady demand for medical devices
November 19, 2024 / Medtronic Profit Forecast / Demand for Medical Devices / Medtronic Revenue Growth / Healthcare Device Market Trends
Medtronic raised its annual profit forecast amid strong demand for medical devices, though investor expectations remained high. Revenue growth was robust across most segments, with normalization anticipated in the medical surgical unit despite regional slowdowns.
Incyte sinks on setback for drugs acquired in $750M buyout
November 19, 2024 / Incyte Drug Development Setback / Jakafi Revenue Dependency / Incyte Pipeline Challenges / Povorcitinib Phase 3 Trials
Incyte paused a Phase 2 trial for INCB000262 due to toxicology concerns and scrapped INCB000547 after disappointing results. These setbacks challenge its diversification from Jakafi, intensifying focus on pipeline developments like povorcitinib for autoimmune conditions.
Citizen Health secures $14.5M in seed funding for rare disease drug development
November 19, 2024 / Rare Disease Drug Development / Citizen Health Funding News / AI in Rare Disease Research
Citizen Health raised $14.5M in seed funding to advance rare disease drug development. Its AI-driven platform centralizes clinical data and patient outcomes, accelerating research and empowering patients with personalized health insights.
Northwestern Medicine announces international healthcare collaboration
November 19, 2024 / Northwestern Medicine International Collaboration / London Clinic Healthcare Partnership / Advancing Patient Outcomes / International Healthcare
Northwestern Medicine and The London Clinic have partnered to enhance healthcare innovation, research, and patient outcomes. This collaboration aims to share clinical expertise, optimize operational efficiencies, and expand access to advanced treatments globally.
DigitalOwl, ExamOne partner for medical record retrieval, analysis
November 19, 2024 / DigitalOwl ExamOne Partnership / Generative AI Medical Records / Medical Record Retrieal Technology
DigitalOwl and ExamOne have partnered to streamline medical record retrieval and analysis using generative AI. This collaboration enhances efficiency for insurance and legal professionals, improving underwriting, risk assessment, and claims review processes.
// Legal & Regulatory
With patent settlement, BeiGene defends blockbuster Brukinsa from MSN’s generic threat until 2037
November 19, 2024 / BeiGene Brukinsa / Patent Settlement / Brukinsa Blockbuster Delay / Cancer Drug / MSN Pharmaceuticals Settlement / Oncology Market Exclusivity
BeiGene settled with MSN Pharmaceuticals, delaying generic Brukinsa launches until 2037, ensuring market exclusivity for its blockbuster cancer drug. The resolution secures Brukinsa’s growth trajectory amid ongoing patent and intellectual property disputes with AbbVie.
EC approval for Pfizer’s Hympavzi
November 20, 2024 / Hympavzi European Approval / Marstacimab Hemophilia Treatment / Pfizer
The European Commission approved Pfizer’s Hympavzi (marstacimab) for preventing bleeding episodes in patients with severe hemophilia A or B. It’s the first anti-TFPI therapy in the EU, offering once-weekly, subcutaneous administration via auto-injector.
Roche files patent suit to fend off potential Evrysdi generics from Zydus, Natco
November 20, 2024 / Roche Evrysdi Patent Lawsuit / SMA Drug Generics Challenge / Natco Zydus Evrysdi Infringement / Spinal Muscular Atrophy Treatment
Roche has filed lawsuits against Natco Pharma and Zydus Lifesciences to protect Evrysdi’s patents from generic challenges. The oral SMA drug, a significant growth driver for Roche, is also being tested in innovative combination therapies.
FDA shares additional draft guidance on CGTs
November 19, 2024 / FDA Cell and Gene Therapy Guidance / CGT IND Submission FAQs / dSafety Monitoring in CGT Trials
The FDA issued draft guidance on cell and gene therapy (CGT) development, addressing IND submissions, pre-BLA meeting recommendations, and safety monitoring in clinical trials. The guidance aims to streamline reviews and enhance trial safety protocols.
Rapid growth spurt for UCB’s Bimzelx continues with hidradenitis suppurativa nod marking 5th FDA approval
November 20, 2024 / Bimzelx Hidradenitis Suppurative Apporval / UCB Immunology Blockbuster
UCB’s Bimzelx earned its fifth FDA approval, now for hidradenitis suppurativa (HS). The IL-17A/F inhibitor offers a promising option for HS, an intensely painful condition, and strengthens its position as a key immunology blockbuster.
// Research & Development
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
November 19, 2024 / Dapirolizumba Pegal Phase 3 Results / Systemic Lupus Erythematosus Treatment / Clinical Trials / UCB Biogen Lupus Drug Development
Phase 3 results for dapirolizumab pegol (DZP) demonstrated significant reductions in systemic lupus erythematosus (SLE) activity and improved corticosteroid tapering. The novel anti-CD40L therapy showed a favorable safety profile and is advancing in clinical development by UCB and Biogen.
Cardiovascular Researchers Dramatically Reduce Size and Severity of Stroke Using Antidiabetic Drug in Preclinical Models
November 19, 2024 / Empagliflozin Stroke Treatment / Antidiabetic Drugs in Stroke Care / Ischemic Stroke Size Reduction / HMRI Storke Reasearch Findings
Huntington Medical Research Institutes demonstrated that empagliflozin, an antidiabetic drug, significantly reduces stroke size and brain swelling in preclinical models. The findings suggest potential future use for stroke prevention and acute treatment, pending further research.
Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling
November 19, 2024 / Clanozepam Overdose Risks / Safety Notice / Mislabeled Packaging
Endo expanded its voluntary recall of Clonazepam Orally Disintegrating Tablets due to potential carton strength mislabeling. While internal packaging reflects the correct dosage, mislabeling poses risks of overdose, including sedation and respiratory depression, especially in vulnerable patients.
CatalYm gaining momentum with GDF-15 neutralizing approach
November 19, 2024 / CatalYm Visugromab Development / Cancer Therapy / Innovative Oncology Solutions
CatalYm’s visugromab, an anti-GDF-15 antibody, is advancing as a promising therapy to counteract cancer treatment resistance. The company closed an oversubscribed $150M Series D financing to propel clinical development and improve patient outcomes.
Merck Gets a Shot of Confidence From Pivotal Test of SubQ Injectable Keytruda
November 19, 2024 / Subcutaneous Keytruda Trial Results / Injectable pembrolizumab formulation / Merck Cancer Immunotherapy Keytruda / Drug Innovation
Merck’s Phase 3 trial demonstrated that subcutaneous Keytruda is comparable to the IV formulation in pharmacokinetics, efficacy, and safety. This injectable version offers a more convenient option for patients and may help Merck counter biosimilar competition.
// Politics
Trump picks Dr. Oz to lead Medicare and Medicaid
November 19, 2024 / Trump / Dr. Oz CMS Appointment / Medicare and Medicaid Leadership / Healthcare Policy / Chronic Disease Healthcare Reforms / CMS Senate Confirmation
President-elect Trump nominated Dr. Mehmet Oz to lead the Centers for Medicare and Medicaid Services (CMS), a key agency overseeing Medicare, Medicaid, and ACA plans. The appointment emphasizes tackling chronic diseases and healthcare system challenges.
Future of Medicare drug price negotiations under new administration: 5 things to know
November 18, 2024 / Medicare Drug Price Negotiations / Inflation Reduction Act Healthcare Policies / Medicare Part D Premium Stabilization / Trump / Drug Price Reforms
The future of Medicare’s drug price negotiation program, a key provision of the Inflation Reduction Act, faces uncertainty under the incoming Trump administration, with potential policy changes, legal challenges, and scrutiny of Medicare Part D premium stabilization efforts.
What might a Trump administration mean for the Biosecure Act?
November 20, 2024 / Biosecure Act / China Relations / Biopharma Manufacturing Policy / China Biotech Partnership Restrictions / Trump
The Biosecure Act, which mandates U.S. biopharma companies to sever ties with specific Chinese firms, faces uncertain passage under the incoming Trump administration. With bipartisan support, the act reflects growing scrutiny of U.S.-China biopharma relations.
Musk, Ramaswamy will lean on Supreme Court rulings to cut US agencies
November 20, 2024 / Musk Ramaswamy Federal Regulation Cuts / Supreme Court Agency Authority Rulings / Trump / Federal Workforce Reduction Pkans / Healthcare Regulatory Impact
Elon Musk and Vivek Ramaswamy aim to reduce federal regulations and agency authority through a Trump-appointed government efficiency panel. Their plans, influenced by recent Supreme Court rulings, could impact healthcare-related policies and federal oversight.
How Will Trump’s Government Impact Health Policy Abroad?
November 18, 2024 / Trump Administration Health Policy / Global Health Impact / Vaccine Skepticism / Public Health / Drug Supply Chain Disruptions
The Trump administration’s potential health policies, including vaccine skepticism, reduced multilateral collaboration, and tariffs, could disrupt global health standards, funding, and drug supply chains. European health systems may face challenges sustaining multilateral health initiatives and addressing drug shortages.